Petrelintide
In a phase 1 trial with 48 people, the group with the largest mean change lost 8.6% of body weight after 16 weeks (PMID 42017294; checked: 2026-08-25). The placebo group lost 1.7% in the same trial part (PMID 42017294; checked: 2026-08-25). Zealand Pharma paid for the work. The firm also paid to prepare the paper.
What is petrelintide?
Petrelintide is a peptide drug being studied for weight loss (PMID 42017294; checked: 2026-08-25). The paper calls it a 37-amino-acid peptide. The United States GSRS sequence has 36 residues. The two main sources differ by one residue. This page does not choose between them.
GSRS lists UNII D78KBY7BRU and CAS 2766385-23-1. It lists ZP-8396 and ZP8396 as names for the same record. These facts were checked on 2026-08-25.
Do the development codes collide?
Exact GSRS searches for Petrelintide, ZP-8396, and ZP8396 returned the same full record. All three names led to one UNII and one name set. No second GSRS identity was found on 2026-08-25.
ClinicalTrials.gov returned one unrelated record because ZP8396 appeared inside a placebo label. NCT06951854 concerns NV01-A02, autism, and sponsor Neuroventi. It is not counted as a Petrelintide trial.
What did the human trial measure?
The paper reports two phase 1 trials that were double-blind, placebo-controlled, and set by chance (PMID 42017294; checked: 2026-08-25). The result above came from MAD part 2. That part had 48 adults with overweight or obesity (PMID 42017294; checked: 2026-08-25).
Mean weight changes after 16 weeks were -4.8%, -8.6%, and -8.3% in the three drug groups (PMID 42017294; checked: 2026-08-25). Placebo changed -1.7% (PMID 42017294; checked: 2026-08-25). The estimated gaps from placebo were -3.2%, -7.0%, and -6.7% (PMID 42017294; checked: 2026-08-25). Each test had p ≤ 0.0002 (PMID 42017294; checked: 2026-08-25).
The figure in PMID 42017294 has 95% confidence bars. The paper gives no numeric limits for this result in its text or table.
Zealand Pharma paid for the work. The conflict statement says Zealand ran the trials and paid for the paper. The sponsor helped shape the plan. It also helped collect data, decide to publish, and prepare the paper.
Four authors worked at Zealand and owned shares (PMID 42017294; checked: 2026-08-25). One author had left Zealand but still owned shares (PMID 42017294; checked: 2026-08-25). Two authors said their institute had received research funds from many firms, including Zealand. One also reported speaking fees, a Zealand travel grant, and paid consulting.
What else did the trial record?
The paper found no serious or severe side effects that began during treatment (PMID 42017294; checked: 2026-08-25). Nausea affected 16.7% to 33.3% of the drug groups in MAD part 2 (PMID 42017294; checked: 2026-08-25). Placebo nausea was 16.7% (PMID 42017294; checked: 2026-08-25). Most stomach and bowel events were mild.
One person stopped treatment after moderate nausea and vomiting (PMID 42017294; checked: 2026-08-25). Diarrhoea was rare. Vomiting in MAD part 2 occurred only in the person who stopped. The paper also reports that all injection-site reactions were mild and short-lived.
The phase 1 trials mainly tested safety, tolerance, and how the drug moved through the body. No formal sample-size calculation was made. The weight test was added after the trial plan was set. These limits were checked in PMID 42017294 on 2026-08-25.
How much human research is registered?
ClinicalTrials.gov lists eight bound trials as of 2026-08-25. Five are phase 1: NCT05096598, NCT05613387, NCT07076030, NCT07338214, and NCT07682818. Three are phase 2: NCT06662539, NCT06926842, and NCT07589686.
Zealand Pharma runs every named trial except NCT07589686. Hoffmann-La Roche runs NCT07589686. None of the named records had posted results on 2026-08-25. A paper still reports results outside the registry, including PMID 42017294.
Evidence tier B shows that human trials exist. It does not prove drug approval. The EudraCT pages gave no count we could read. Their count stays unclear, not zero.
What is petrelintide's EU status?
EU status: investigational. CTIS 2024-512549-18-00 names the drug in a phase 2 trial that was approved. Its decision date was 16 Dec 2024. The trial is now ended.
CTIS 2025-523641-10-00 is an approved trial of how the drug moves through the body. Zealand Pharma runs it. Poland approved it on 7 May 2026. Slovakia approved it on 6 May 2026.
Those records show trial approval, not approval to sell the drug. The name was absent from the EMA central medicines list checked on 2026-08-25. The EMA list does not cover every national approval in an EU state.
When was petrelintide first documented?
No sound month is known for when the drug first circulated. The earliest bound paper in the set is from 2025 (PMID 41217931; checked: 2026-08-25). A paper year and a trial entry do not show when the drug first appeared outside studies. This limit was checked on 2026-08-25.
What do users report?
No full first-person thread about the drug was found in the forum archive we could read. No forum quote or group claim is included.
→ What can be inside a grey-market vial → All compounds in the register